180605-36-1 Usage
Description
2-(4-Methylpiperazin-1-yl)aniline is an organic compound with the molecular formula C11H18N2. It is a derivative of aniline, featuring a methylpiperazinyl group attached to the 2nd carbon of the aniline structure. 2-(4-Methylpiperazin-1-yl)aniline is known for its potential applications in the pharmaceutical and chemical industries due to its unique chemical properties.
Uses
Used in Pharmaceutical Industry:
2-(4-Methylpiperazin-1-yl)aniline is used as a key intermediate in the synthesis of various small molecules, particularly inhibitors of SRC tyrosine kinase. These inhibitors play a crucial role in the development of targeted therapies for cancer treatment, as they help regulate the activity of the SRC protein, which is often overexpressed in various types of cancer cells.
Additionally, 2-(4-Methylpiperazin-1-yl)aniline can be utilized in the development of other therapeutic agents, such as antidepressants and antipsychotics, due to its structural similarity to known active compounds in these drug classes.
Used in Chemical Industry:
In the chemical industry, 2-(4-Methylpiperazin-1-yl)aniline can be employed as a building block for the synthesis of various complex organic molecules, including dyes, pigments, and other specialty chemicals. Its unique structural features make it a valuable component in the design and synthesis of novel materials with specific properties and applications.
Furthermore, the compound can be used in the development of new chemical processes and methodologies, as its reactivity and functional group compatibility can be exploited to achieve selective transformations and improve synthetic efficiency.
Check Digit Verification of cas no
The CAS Registry Mumber 180605-36-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,0,6,0 and 5 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 180605-36:
(8*1)+(7*8)+(6*0)+(5*6)+(4*0)+(3*5)+(2*3)+(1*6)=121
121 % 10 = 1
So 180605-36-1 is a valid CAS Registry Number.
InChI:InChI=1/C11H17N3/c1-13-6-8-14(9-7-13)11-5-3-2-4-10(11)12/h2-5H,6-9,12H2,1H3/p+1
180605-36-1Relevant articles and documents
FLUORESCENT SYSTEMS FOR BIOLOGICAL IMAGING AND USES THEREOF
-
, (2021/02/12)
The invention relates to compounds of formula I, in which Y, Ar1, Ar2, X, R1 and R2 are defined herein, and to their use in a variety of biological imaging techniques and therapeutic methods. In aspects, the invention relates to conjugates comprising the compounds of formula I and their associated uses and therapeutic uses.
Design, synthesis and biological evaluation of piperazino-enaminones as novel suppressants of pro-Inflammatory cytokines
Ghoneim, Ola M.,Bill, Ashley,Dhuguru, Jyothi,Szollosi, Doreen E.,Edafiogho, Ivan O.
, p. 3890 - 3898 (2018/06/14)
Infection triggers the release of pro-inflammatory cytokines (TNF-alpha and IL-6). Over-production, however, cause tissue injury seen in severe asthma. The ability of enaminone E121 to reduce pro-inflammatory cytokines in our laboratory encouraged further examination of its structural scaffold. Piperazino-enaminones were designed by incorporating n-arylpiperazine motif into the aromatic enaminone. Four possible modifications were explored systematically. Synthesis was accomplished by amination of the corresponding methyl/ethyl 2,4-dioxo-6-(substituted)cyclohexane-carboxylate. Sixteen novel compounds were synthesized. Biological activity was tested in J774 macrophages stimulated with lipopolysaccharides. The release of cytokines was measured via ELISA. Four compounds significantly suppressed TNF-alpha and IL-6 release in dose-dependent manner.
Synthesis of benzimidazoles via iridium-catalyzed acceptorless dehydrogenative coupling
Sun, Xiang,Lv, Xiao-Hui,Ye, Lin-Miao,Hu, Yu,Chen, Yan-Yan,Zhang, Xue-Jing,Yan, Ming
, p. 7381 - 7383 (2015/07/15)
Iridium-catalyzed acceptorless dehydrogenative coupling of tertiary amines and arylamines has been developed. A number of benzimidazoles were prepared in good yields. An iridium-mediated C-H activation mechanism is suggested. This finding represents a novel strategy for the synthesis of benzimidazoles.
